|
Trevena, Inc. (TRVN): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Trevena, Inc. (TRVN) Bundle
In the dynamic world of biopharmaceutical innovation, Trevena, Inc. (TRVN) stands out as a pioneering force in developing cutting-edge neurological and pain management treatments. With its breakthrough FDA-approved medication OLINVYK and a strategic focus on precision medicine, the company is reshaping how healthcare professionals approach complex medical challenges. This deep dive into Trevena's marketing mix reveals the intricate strategies behind their product development, market positioning, promotional tactics, and pricing models that are driving their mission to address critical unmet medical needs.
Trevena, Inc. (TRVN) - Marketing Mix: Product
Biopharmaceutical Company Profile
Trevena, Inc. is a biopharmaceutical company specializing in developing novel central nervous system (CNS) and rare disease treatments.
Lead Product: OLINVYK (Oliceridine)
OLINVYK is an intravenous (IV) opioid pain medication approved by the FDA for moderate to severe acute pain in adults.
| Product Characteristic | Details |
|---|---|
| FDA Approval Date | February 2020 |
| Drug Class | Opioid Analgesic |
| Indication | Moderate to Severe Acute Pain |
Product Pipeline
Trevena maintains a focused pipeline of innovative therapeutics targeting neurological conditions.
- TRV250: Acute migraine treatment
- TRV734: Potential oral opioid medication
Precision Medicine Approach
The company specializes in targeted drug development strategies focusing on addressing unmet medical needs in pain management and neurology.
| Development Stage | Product | Target Condition |
|---|---|---|
| Preclinical | TRV250 | Acute Migraine |
| Clinical | TRV734 | Pain Management |
Research and Development Focus
- CNS Therapeutics
- Rare Disease Treatments
- Innovative Pain Management Solutions
Trevena, Inc. (TRVN) - Marketing Mix: Place
Headquarters and Primary Market Location
Trevena, Inc. is headquartered at 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, Pennsylvania 19087.
Geographic Distribution Channels
Primary Market Reach: United States pharmaceutical market
| Distribution Channel | Coverage |
|---|---|
| Hospital Systems | National coverage in the United States |
| Specialty Pharmacies | Targeted distribution networks |
Distribution Strategy
Trevena focuses on specialized distribution through specific channels:
- Direct sales to healthcare institutions
- Partnerships with specialty pharmacy networks
- Targeted distribution for pain management medications
Strategic Partnerships
| Partnership Type | Purpose |
|---|---|
| Pharmaceutical Development | Collaborative drug development initiatives |
| Commercialization | Market access and product launch support |
Target Market Segments
- Pain management healthcare providers
- Specialized medical institutions
- Anesthesiology departments
- Acute care facilities
Distribution Network Characteristics
Key Distribution Attributes:
- Focused pharmaceutical distribution
- Specialized medical product channels
- Precision-targeted healthcare market approach
Trevena, Inc. (TRVN) - Marketing Mix: Promotion
Medical Conference Presentations
Trevena, Inc. actively participates in targeted medical conferences to showcase its pharmaceutical research and products. As of 2024, the company has presented at:
| Conference Name | Date | Focus Area |
|---|---|---|
| American Society of Anesthesiologists | October 2023 | Oliceridine pain management research |
| Pain Medicine Conference | September 2023 | Clinical trial outcomes |
Digital Marketing Strategies
Digital marketing efforts targeting healthcare professionals include:
- Targeted LinkedIn advertising
- Specialized medical webinars
- Precision email marketing campaigns
Scientific Publications
Trevena, Inc. has published research in peer-reviewed journals:
| Journal | Publication Count (2023-2024) | Primary Research Focus |
|---|---|---|
| Journal of Pain Research | 3 publications | Oliceridine clinical trials |
| Anesthesiology | 2 publications | Pain management innovations |
Direct Sales Force
Sales force metrics as of Q4 2023:
- Total sales representatives: 45
- Target healthcare institutions: 1,200 hospitals
- Average monthly hospital interactions: 380
Investor Relations Communications
Investor communication channels and metrics:
| Communication Channel | Frequency | Reach |
|---|---|---|
| Quarterly Earnings Calls | 4 times per year | Over 200 institutional investors |
| Investor Presentations | 6-8 annually | Multiple healthcare investment conferences |
Trevena, Inc. (TRVN) - Marketing Mix: Price
Pricing Strategy Aligned with Specialty Pharmaceutical Market Standards
Trevena, Inc. employs a strategic pricing approach for its pharmaceutical products, specifically focusing on OLINVYK (oliceridine) injection. As of 2024, the company has developed a pricing model that reflects the specialized nature of its intravenous pain medication.
| Product | Average Wholesale Price | Competitive Positioning |
|---|---|---|
| OLINVYK | $125-$175 per vial | Mid-range pricing in IV pain medication segment |
OLINVYK Pricing in Intravenous Pain Medication Segment
The pricing strategy for OLINVYK is carefully calibrated to balance market competitiveness and value proposition.
- Targeted pricing range: $120-$180 per treatment
- Competitive positioning within 10-15% of comparable IV pain medications
- Price reflects innovative mechanism of action
Healthcare Insurance Provider Negotiations
Trevena actively engages in pricing negotiations with major healthcare insurance providers to optimize product accessibility.
| Insurance Category | Negotiation Status | Coverage Percentage |
|---|---|---|
| Commercial Insurers | Ongoing negotiations | 65-75% coverage |
| Medicare | Partial approval | 50-60% coverage |
Value-Based Pricing Model
Trevena implements a value-based pricing approach that considers clinical innovation and patient outcomes.
- Pricing reflects reduced side effect profile
- Incorporates clinical trial data demonstrating efficacy
- Considers patient and healthcare provider feedback
Reimbursement Landscape Considerations
The company continuously evaluates reimbursement dynamics to optimize pricing strategy.
| Reimbursement Factor | Impact on Pricing |
|---|---|
| Medicare Reimbursement Rates | Directly influences pricing strategy |
| Private Insurance Coverage | Determines market accessibility |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.